Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Summary
This is a prospective, single-center, single-arm, phase 2 study. This study aims to evaluate the efficacy and safety of Anti-lymphocyte globulin plus herombopag in combination with moderate-dose cyclophosphamide for severe aplastic anemia.
Key Details
Gender
All
Age Range
12 Years - Any
Study Type
INTERVENTIONAL
Enrollment
43
Start Date
2023-07-10
Completion Date
2025-12-31
Last Updated
2024-09-25
Healthy Volunteers
No
Conditions
Interventions
Cyclophosphamide added to standard immunosuppressive therapy with herombopag
Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. The moderate-dose cyclophosphamide (20mg/kg) will be administered on days 29-30 and days 43-44.
Locations (1)
Regenerative Medicine Center
Tianjin, Tianjin Municipality, China